Á¦ ¸ñ 2009 °¢ Çмú»ó ¼ö»óÀÚ °øÁö
ÀÛ¼ºÀÚ ÇÐȸ°ü¸®ÀÚ ÀÛ¼ºÀÏ 2009-06-16
÷ ºÎ ÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù. Á¶ ȸ 3081
´ëÇѾÏÇÐȸ¿¡¼­ ½ÃÇàÇÏ°í ÀÖ´Â °¢ Çмú»ó¿¡ ´ëÇÑ ½Ã»ó½ÄÀÌ Áö³­ 6¿ù 12ÀÏ ¼­¿ï·Ôµ¥È£ÅÚ¿¡¼­ °³ÃÖµÈ Á¦ 35Â÷ ´ëÇѾÏÇÐȸ ÃÑȸ¿¡¼­ °ÅÇàµÇ¾úÀ¸¸ç, ¼ö»óÀÚ¿¡°Ô´Â Çмú»ó±Ý°ú »óÀåÀÌ ¼ö¿©µÇ¾ú½À´Ï´Ù.


¡Û Á¦12ȸ Çѱ¹¾Ï¿¬±¸Àç´Ü Çмú»ó(2008³â ´ëÇѾÏÇÐȸÁö °ÔÀç³í¹®, »ó±Ý °¢ 250¸¸¿ø)

1) Ãæ³²ÀÇ´ë ³»°ú Á¶´ö¿¬
Cytoplasmic Trapping of CXCR4 in Hepatocellular Carcinoma Cell Lines

2) ´Ü±¹ÀÇ´ë º´¸®°ú ¸í³ªÇý
Cyclin D1 Overexpression, p16 Loss, and pRb Inactivation Play a Key Role in Pulmonary Carcinogenesis and have a Prognostic Implication for the Long-term Survival in Non-small Cell Lung Carcinoma Patients

¡Û Á¦1ȸ ´ëÇѾÏÇÐȸ ±âÃÊ¿ì¼ö³í¹®»ó(2008³â ´ëÇѾÏÇÐȸÁö °ÔÀç³í¹®, »ó±Ý °¢ 250¸¸¿ø)

1) °í·ÁÀÇ´ë ³»°ú ±è¿­È«
Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer

2) ÀÎõ´ëÇб³ »ý¹°Çаú À̹̰¡¿¤
Differential Physiological Effects of Raf-1 Kinase Pathways Linked to Protein Kinase C Activation Depending on the Stimulus in v-H-ras-transformed Cells


¡Û Á¦9ȸ »ç³ëÇÇ-¾Æº¥Æ¼½º Çмú»ó (2008³â ´ëÇѾÏÇÐȸÁö °ÔÀç³í¹®, »ó±Ý °¢ 200¸¸¿ø)

1) ¼­¿ïÀÇ´ë ¼Ò¾Æ°ú ½ÅÈñ¿µ
Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea

2) ¼­¿ïÀÇ´ë ³»°ú ÀÓ¼®¾Æ
Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer

3) µ¿¾ÆÀÇ´ë ³»°ú ±èÈ¿Áø
Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer

4) Áß¾ÓÀÇ´ë ³»°ú ÀÌ»óÀç
A Phase II Study of Leucovorin, 5-FU and Docetaxel Combination Chemotherapy in Patients with Inoperable or Postoperative Relapsed Gastric Cancer

5) °í½ÅÀÇ´ë ³»°ú ±è¾ç¼ö
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity


¡Û Á¦ 1ȸ ·Î½´¾ÏÇмú»ó (2008³â ´ëÇѾÏÇÐȸÁö °ÔÀç³í¹®, »ó±Ý °¢ 200¸¸¿ø)
1) °æÈñÀÇ´ë ³»°ú ±è½Ã¿µ
Clinical Significance of Lymph Node Micrometastasis in Stage I and II Colon Cancer

2) µ¿±¹ÀÇ´ë ³»°ú ±èµµ¿¬
Discrepant Views of Korean Medical Oncologists and Cancer Patients on Complementary and Alternative Medicine

3) ÀÎÁ¦ÀÇ´ë ³»°ú ±è¼º·Ï
A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer

4) °¡Å縯ÀÇ´ë »êºÎÀΰú ¹ÚÁ¾¼·
The Increasing Frequency of Cervical Cancer in Korean Women under 35

5) °æºÏÀÇ´ë ¿Ü°ú À¯¿Ï½Ä
Prognostic Significance of Serum and Tissue Carcinoembryonic Antigen in Patients with Gastric Adenocarcinomas

6) °¡Å縯ÀÇ´ë ³»°ú °­ÁøÇü
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea

7) °í·ÁÀÇ´ë ºñ´¢±â°ú °­¼®È£
A Matched-cohort Comparison of Laparoscopic Renal Cryoablation using Ultra-thin Cryoprobes with Open Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma

8) °í½ÅÀÇ´ë ¿Ü°ú ¹é½Â¾ð
Clinical Characteristics of Multiple Primary Colorectal Cancers

9) °üµ¿ÀÇ´ë »êºÎÀΰú ±èÀç¿í
Endometrial Stromal Sarcomas: A Retrospective Analysis of 28 Patients, Single Center Experience for 20 Years

10) °í·ÁÀÇ´ë ³»°ú ±èÁؼ®
The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer


¡ÛÁ¦6ȸ ¿ì¼ö¿¬±¸ÀÚ»ó (ÇØ¿Ü SCIµîÀç³í¹®, Âü°í¹®Çå ¾ÏÇÐȸÁö³í¹®Àοë, »ó±Ý °¢250¸¸¿ø)

1) °í·Á´ëÇб³ »ý¸í°úÇдëÇÐ Áö¼º±æ
Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses (Int J Cancer. 2008;122: 1573–84)

2) °è¸íÀÇ´ë ³»°ú ¼ÛÈ«¼®
Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group (Br J Cancer. 2008;98:542-6)

3) ±¹¸³¾Ï¼¾ÅÍ ¿Ü°ú ±è¿µ¿ì
Improved Quality of Life Outcomes After Laparoscopy-Assisted Distal Gastrectomy for Early Gastric Cancer Results of a Prospective Randomized Clinical Trial (Ann Surg. 2008;248:721-7)

4) ¼­¿ïÀÇ´ë ³»°ú ±èÅÂÀ¯
Gene Silencing of TSPYL5 mediated by abrrant promoter methylation in gastric cancers (Lab Invest. 2008;88:153-60)

¡Û Á¦ 1ȸ ¸±¸®¾ÏÇмú»ó

1) ÃÖ°í IFÀÇ SCI Àú³Î¿¡ ¾ÏÇÐȸÁö¸¦ ÀοëÇÑ ³í¹®, »ó±Ý 500¸¸¿ø
; ÀÎÇÏÀÇ´ë ³»°ú ·ùÁ¤¼±
Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Patients Treated With Platinum-Based Chemotherapy (J Clin Oncol. 2008;26:5972-9)

2) ´Ù¼öÀÇ SCI Àú³Î¿¡ ¾ÏÇÐȸÁö¸¦ ÀοëÇÑ Ã¥ÀÓÀúÀÚ, »ó±Ý 500¸¸¿ø
; ¼­¿ï¾Æ»êº´¿ø ³»°ú °­À±±¸ (4Æí Àοë)

- Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane (Am J Clin Oncol-Cancer Clin Trials 2008;31:151-6)

- A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer (Cancer Chemother Pharmacol. 2008;63:1-8)

- A phase ¥± study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy (Cancer Chemoth Pharm. 2008;61:631-7)

- A phase ¥± study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer (Brit J Cancer. 2008;98:316-22)


¡Û Á¦ 1ȸ ¸ÓÅ©¼¼·Î³ë ¾ÏÇмú ¿¬±¸ºñ (»ó±Ý °¢1,000¸¸¿ø)

1) ¼­¿ï´ë º¸¶ó¸Åº´¿ø ¿Ü°ú Ȳ±âÅÂ
»ïÁßÀ½¼º À¯¹æ¾Ï¿¡¼­ array comparative genomic hybridization ºÐ¼®¿¡ ÀÇÇØ ¼±Á¤µÈ PHB À¯ÀüÀÚÀÇ ¿ªÇÒ¿¡ ´ëÇÑ °ËÁõ

2) °í·ÁÀÇ´ë ³»°ú ¹Ú°æÈ­
Triple negative breast cancer ȯÀÚ¿¡¼­ ½Åº¸Á¶ Ç×¾ÏÁ¦ Ä¡·á ÈÄ ¹ÝÀÀ ¿¹ÃøÀ» À§ÇÑ Á¶±â »ý¹°ÇÐÀû Ç¥ÁöÀÚ ¹ß±¼¿¡ °üÇÑ ¿¬±¸


¡Û Á¦11ȸ GSK Çмú»ó ¼ö»óÀÚ (Çмú´ëȸ ¿ì¼ö¿¬Á¦, »ó±Ý °¢100¸¸¿ø)

1) ¼­¿ïÀÇ´ë ¾Ï¿¬±¸¼Ò À±¿µ±¤
Combination of EGFR and MEK1/2 Inhibitor Shows Synergistic Effects by Suppressing EGFR/HER3-Dependent AKT Activation in Human Gastric Cancer cells

2) ¿øÀÚ·ÂÀÇÇпø ¹æ»ç¼±ÀÇÇבּ¸¼Ò ÀÌÇØÁØ
Recovery of Radiation-Induced Bone Marrow Suppression by HSP25 Through Tie2 signaling

3) °í·Á´ëÇб³ »ý¸í°øÇаú À̹α¸
RASSF1A Suppresses RhoA-induced Tumor Cell Invasion through Smurf1-mediated RhoA ubiquitinylation

4) °æºÏÀÇ´ë ³»°ú ±èÁ¾±¤
IVS10+12A>G polymorphism in the hMSH2 gene associated with prognosis for patients with colorectal cancer

5) ¿¬¼¼ÀÇ´ë ³»°ú ±èÈ¿¼Û
Efficacy and Toxicity Profile of Sunitinib for Korean Patients with Advanced Renal Cell Carcinoma

6) ¼º±Õ°üÀÇ´ë ³»°ú ±è½ÂÅÂ
Risk stratification by hormonal receptor (ER, PgR) and HER-2 status in small (¡Â1cm) invasive breast cancer: Who might be a possible candidate for adjuvant treatment?

7) µ¿±¹ÀÇ´ë »êºÎÀΰú ³ëÁÖ¿ø
Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korea

8) ¼º±Õ°üÀÇ´ë ³»°ú ¾öÁöÀº
Comparison of Erlotinib versus Gefitinib as the Second Line Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Randomized Phase II Trial